MOG and myeloid sarcoma: Hesperidin (50–200 mg/kg for 25 days orally) in the myelin oligodendrocyte glycoprotein (MOG)-induced mouse model of MS can reduce the expression of pro-inflammatory cytokines (IL-6, IL-17, and TNF-α) and increase the expression of anti-inflammatory cytokines (IL-10 and TGF-β).